Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Febuxostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 11/20 | 1.00 |
| ▸ | TARBP2 | Q15633 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | BLVRB | P30043 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | PPID | Q08752 | 1/20 | 0.67 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Febuxostat SCHEMBL30161803 | 1.00 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL28271887 | 1.00 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL29398803 | 1.00 | XDH (1.00) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL27935500 | 0.99 | XDH (0.98) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL27935497 | 0.99 | XDH (0.98) | XDHTARBP2ABCC4ABCB11PGR | |
| Febuxostat SCHEMBL2635494 | 0.98 | XDH (0.96) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL437353 | 0.92 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL23417559 | 0.92 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL16363788 | 0.92 | XDH (0.85) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL436720 | 0.91 | XDH (0.83) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4328 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12635917-B2 | Remote blood volume monitor | DAXOR CORP. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260130854-A1 | PREPARATION OF NANO LINIMENT FOR EXTERNAL TREATMENT OF GOUT | Zhang, Boke (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130853-A1 | METHOD OF TREATING GOUT BY TOPICAL APPLICATION OF NANO LINIMENT | Zhang, Boke (US) | 2026-05-14 | — | — | US | claimed |
| CN-122010656-A | Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl | 陕西师范大学 | 2026-05-12 | — | — | CN | claimed |
| WO-2026090536-A1 | METHODS AND USES FOR TREATING NK CELL OR T-CELL LYMPHOMAS OR LEUKEMIAS WITH ANTI-CD94 ANTIBODIES | DREN BIO MANAGEMENT, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12590075-B2 | Refining method | NGK INSULATORS, LTD. (JP) | 2026-03-31 | — | — | US | claimed |
| US-12539273-B2 | External nano liniment for gout and preparation method thereof | Zhang, Boke (US) | 2026-02-03 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| WO-2007019153-A2 | METHODS FOR TREATING HYPERTENSION | TAP PHARMACEUTICAL PRODUCTS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| WO-2006121995-A2 | METHODS FOR TREATING NEPHROLITHIASIS | TAP PHARMACEUTICAL PRODUCTS, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| US-20060252808-A1 | Methods for treating nephrolithiasis | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2006-11-09 | — | — | US | claimed |
| CN-1785182-A | Glassiness sosoloid contg. 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazol formic-acid and polyvinyl pyrrolidone and its prepn. method | TAIPU PHARMACEUTICAL SCIENCE A (CN) | 2006-06-14 | — | — | CN | claimed |
| US-20060106036-A1 | Tumorigenesis inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-18 | — | — | US | claimed |
| EP-1609479-A1 | TUMORIGENESIS INHIBITOR | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | claimed |
| CN-1642546-A | Solid preparation containing single crystal form | TEIJIN LTD (JP) | 2005-07-20 | — | — | CN | claimed |
| US-6225474-B1 | REGULATES BIOSYNTHESIS OF URIC ACID IN VIVO AND USED FOR THERAPY OF HYPERURICEMIA | TEIJIN LIMITED (JP) | 2001-05-01 | — | — | US | claimed |
| CN-1275126-A | Polymorphs of 2- (3-cyano-4-isobutoxyphenyl) -4-methyl-5-thiazolecarboxylic acid and preparation method thereof | TEIJIN LTD (JP) | 2000-11-29 | — | — | CN | claimed |
| EP-1020454-A1 | POLYMORPHIC MODIFICATIONS OF 2-(3-CYANO-4-ISOBUTYLOXYPHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID AND PROCESSES FOR THE PREPARATION THEREOF | TEIJIN LIMITED (JP) | 2000-07-19 | — | — | EP | claimed |